Our focus in the clinic is on advancing our lead candidate HTD1801 in cardiovascular-kidney-metabolic (CKM) diseases. Based on its dual mechanism of action we are particularly focused on diseases driven by insulin resistance and chronic inflammation. In addition to our lead candidate, we have a growing discovery portfolio.
HighTide Therapeutics focuses on cardiovascular-kidney-metabolic (CKM) diseases and is committed to explore the underlying interconnections within these conditions, identifying unmet clinical needs, and developing innovative therapeutic solutions based on these insights.
June 8, 2026
HighTide Therapeutics Announces Publication of Phase III Results of HTD1801 in NEJM Evidence, Highlighting Foundational Potential in CKM Diseases
June 6, 2026
ADA 2026 |HighTide Therapeutics Presents Datafrom Three HTD1801 Studies, Highlighting Foundational Therapeutic Potential in CKM Diseases
June 4, 2026
ERA 2026 | HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation